Mr. Heron joined Frazier Healthcare in 1999 as an associate and became a General Partner in 2005. Mr. Heron is a member of the firm's Biopharma Venture team. He focuses on early and late-stage private and public biotechnology and specialty pharmaceutical investments. He has been active in forming companies and founding investments including Marcadia Biotech (sold to Roche in 2010), a diabetes and obesity company, Calixa (sold to Cubist in 2009), Cerexa (sold to Forest in 2007), both anti-infectives companies; and Trubion Pharmaceuticals, next generation antibody therapeutics (sold to Emergent BioSolutions in 2010). In specialty pharmaceuticals, he led Frazier’s involvement in a respiratory company, MedPointe (sold to Meda AB in 2007).


He is currently on the boards of Collegium, Kalidex, Precision Dermatology, QuatRx, Silvergate, Tobira and VentiRx.


Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales force optimization, corporate partnering and research prioritization. He was a Phi Beta Kappa graduate and Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.

Feel free to contact him at patrick@frazierhealthcare.com